Xing L et al. |
Osteoclast precursors, RANKL/RANK, and immunology. |
2005 |
Immunol. Rev. |
pmid:16313338
|
Tanaka S et al. |
Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. |
2005 |
Immunol. Rev. |
pmid:16313339
|
Horowitz MC et al. |
B cells and osteoblast and osteoclast development. |
2005 |
Immunol. Rev. |
pmid:16313346
|
Clowes JA et al. |
The role of the immune system in the pathophysiology of osteoporosis. |
2005 |
Immunol. Rev. |
pmid:16313351
|
Walsh NC et al. |
Rheumatic diseases: the effects of inflammation on bone. |
2005 |
Immunol. Rev. |
pmid:16313352
|
Liu Y et al. |
[Effect of Herba Epimedii Flavone on expression of OPG and RANKL in rat osteoblasts]. |
2005 |
Zhong Yao Cai |
pmid:16568663
|
Wang YD et al. |
[Predominant effect of bushen ningxin decoction on postmenopausal osteoporosis in mice]. |
2005 |
Zhongguo Zhong Xi Yi Jie He Za Zhi |
pmid:16355616
|
Xiao HL et al. |
[Expression and activity determination of TNFR domain of osteoprotegerin in E.coli and corresponding antibody preparation]. |
2005 |
Yi Chuan |
pmid:16257908
|
Liu W et al. |
Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. |
2005 |
J. Biol. Chem. |
pmid:16260781
|
Hormdee D et al. |
Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. |
2005 |
Clin. Exp. Immunol. |
pmid:16297161
|
Geusens P and Reid D |
Newer drug treatments: their effects on fracture prevention. |
2005 |
Best Pract Res Clin Rheumatol |
pmid:16301192
|
Hamdy NA |
Osteoprotegerin as a potential therapy for osteoporosis. |
2005 |
Curr Osteoporos Rep |
pmid:16303111
|
Wiercinska-Drapalo A et al. |
Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. |
2005 |
Prostaglandins Other Lipid Mediat. |
pmid:16303613
|
Burton DW et al. |
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. |
2005 |
Prostate |
pmid:15389781
|
Zahanich I et al. |
Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. |
2005 |
J. Bone Miner. Res. |
pmid:16059635
|
Cao JJ et al. |
Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. |
2005 |
J. Bone Miner. Res. |
pmid:16059637
|
Terpos E et al. |
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. |
2005 |
Leukemia |
pmid:16079895
|
Stenman UH et al. |
Prognostic value of serum markers for prostate cancer. |
2005 |
Scand J Urol Nephrol Suppl |
pmid:16019759
|
Guang-da X et al. |
Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. |
2005 |
J. Clin. Endocrinol. Metab. |
pmid:16046585
|
Kazama JJ et al. |
Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. |
2005 |
Clin. Nephrol. |
pmid:16047647
|
Olesen P et al. |
Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. |
2005 |
Diabetologia |
pmid:15700136
|
Pantouli E et al. |
Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. |
2005 |
Biochem. Biophys. Res. Commun. |
pmid:15721297
|
Korcok J et al. |
P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. |
2005 |
J. Biol. Chem. |
pmid:15722352
|
Kiviranta R et al. |
Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. |
2005 |
Bone |
pmid:15664014
|
Avbersek-Luznik I et al. |
Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? |
2005 |
Nephrol. Dial. Transplant. |
pmid:15665031
|
Bhatia P et al. |
Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. |
2005 |
Clin. Cancer Res. |
pmid:15671541
|
Schneider HG and Sentry J |
Multiple myeloma. |
2005 |
N. Engl. J. Med. |
pmid:15736296
|
Bock O et al. |
Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. |
2005 |
J. Pathol. |
pmid:15726648
|
Skládal P et al. |
Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. |
2005 |
Biosens Bioelectron |
pmid:15741072
|
Mosheimer BA et al. |
Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. |
2005 |
J. Clin. Endocrinol. Metab. |
pmid:15728209
|
Kanno T et al. |
Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation. |
2005 |
J. Oral Maxillofac. Surg. |
pmid:15742288
|
Han KO et al. |
The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. |
2005 |
Clin. Endocrinol. (Oxf) |
pmid:15730418
|
Nagasaki T et al. |
Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. |
2005 |
Eur. J. Endocrinol. |
pmid:15757850
|
Rhee EJ et al. |
The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. |
2005 |
Am. J. Obstet. Gynecol. |
pmid:15846185
|
Rasmussen LM and Ledet T |
Osteoprotegerin and diabetic macroangiopathy. |
2005 |
Horm. Metab. Res. |
pmid:15918117
|
Tanabe N et al. |
IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. |
2005 |
Life Sci. |
pmid:15921993
|
Zhou YQ et al. |
[OPG and OPGL expression in condyle cartilage of temporomandibular joint following anterior disc displacement]. |
2005 |
Shanghai Kou Qiang Yi Xue |
pmid:16155701
|
Crisafulli A et al. |
Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. |
2005 |
Clin. Sci. |
pmid:15926884
|
Holen I et al. |
Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? |
2005 |
Breast Cancer Res. Treat. |
pmid:16155791
|
Mahamed DA et al. |
G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. |
2005 |
Diabetes |
pmid:15855336
|
Hong JS et al. |
Maternal plasma osteoprotegerin concentration in normal pregnancy. |
2005 |
Am. J. Obstet. Gynecol. |
pmid:16157103
|
Leder BZ and Finkelstein JS |
Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. |
2005 |
Osteoporos Int |
pmid:15856361
|
Mazziotti G et al. |
Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. |
2005 |
J. Bone Miner. Res. |
pmid:15746993
|
Galli C et al. |
Comparison of human mandibular osteoblasts grown on two commercially available titanium implant surfaces. |
2005 |
J. Periodontol. |
pmid:15857069
|
Stolina M et al. |
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. |
2005 |
J. Bone Miner. Res. |
pmid:16160733
|
Corey E et al. |
Osteoprotegerin in prostate cancer bone metastasis. |
2005 |
Cancer Res. |
pmid:15753366
|
Suzuki K et al. |
Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. |
2005 |
Diabetes Res. Clin. Pract. |
pmid:15860239
|
Yasuda H |
[OPG, anti-rANKL antibody]. |
2005 |
Nippon Rinsho |
pmid:16164225
|
Moschen AR et al. |
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. |
2005 |
Gut |
pmid:15753532
|
Choi BK et al. |
Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. |
2005 |
J. Periodontol. |
pmid:15898943
|
Mandelin J et al. |
Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. |
2005 |
J. Biomed. Mater. Res. Part B Appl. Biomater. |
pmid:15768436
|
Crisafulli A et al. |
Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. |
2005 |
Menopause |
pmid:15772566
|
Mizuno N et al. |
Characterization of epithelial cells derived from periodontal ligament by gene expression patterns of bone-related and enamel proteins. |
2005 |
Cell Biol. Int. |
pmid:15774307
|
Indridason OS et al. |
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. |
2005 |
Osteoporos Int |
pmid:15776220
|
Deftos LJ |
Treatment of Paget's disease--taming the wild osteoclast. |
2005 |
N. Engl. J. Med. |
pmid:16135831
|
Li F et al. |
Annexin II stimulates RANKL expression through MAPK. |
2005 |
J. Bone Miner. Res. |
pmid:15940368
|
Cundy T et al. |
Recombinant osteoprotegerin for juvenile Paget's disease. |
2005 |
N. Engl. J. Med. |
pmid:16135836
|
Sen O et al. |
The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. |
2005 |
Neurol. Res. |
pmid:15949247
|
Bock O et al. |
Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. |
2005 |
Br. J. Haematol. |
pmid:15982347
|
Heinrich J et al. |
CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. |
2005 |
Arch. Oral Biol. |
pmid:16137499
|
Fiore CE et al. |
Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. |
2005 |
Osteoporos Int |
pmid:15983730
|
Avignon A et al. |
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. |
2005 |
Diabetes Care |
pmid:16123486
|
Atkins GJ et al. |
Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. |
2005 |
J. Cell. Physiol. |
pmid:15573398
|
Amizuka N et al. |
Histological evaluation for "bone quality" on two mouse models with different bone remodeling. |
2005 |
J. Bone Miner. Metab. |
pmid:15984413
|
Ziegler S et al. |
Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. |
2005 |
Metab. Clin. Exp. |
pmid:15988704
|
Sakai A et al. |
Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice. |
2005 |
J. Bone Miner. Metab. |
pmid:15616888
|
Sasaki N et al. |
Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). |
2005 |
J. Bone Miner. Metab. |
pmid:15616893
|
Masui T et al. |
Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. |
2005 |
Biomaterials |
pmid:15576143
|
Andelković Z et al. |
[Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent]. |
2005 Jul-Aug |
Med. Pregl. |
pmid:16296579
|
Palma MA and Body JJ |
Usefulness of bone formation markers in breast cancer. |
2005 Jul-Sep |
Int. J. Biol. Markers |
pmid:16240842
|
Contractor T et al. |
Osteoclasts resorb protein-free mineral (Osteologic discs) efficiently in the absence of osteopontin. |
2005 Mar-Apr |
In Vivo |
pmid:15796195
|
Buemi M et al. |
Osteoprotegerin, IL-6, IL-1, TNF-alpha and TGF-beta concentrations during acetate-free biofiltration. |
2005 Mar-Apr |
J. Nephrol. |
pmid:15931642
|
Gorczynski RM et al. |
Neutral buoyancy and sleep-deprived serum factors alter expression of cytokines regulating osteogenesis. |
2005 May-Jun |
Acta Astronaut |
pmid:15835039
|
Pettersen I et al. |
Osteoprotegerin is expressed in colon carcinoma cells. |
2005 Nov-Dec |
Anticancer Res. |
pmid:16309167
|
Kraj M et al. |
Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. |
2005 Sep-Oct |
Arch. Immunol. Ther. Exp. (Warsz.) |
pmid:16314829
|
Zojer N et al. |
Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. |
2005 Sep-Oct |
Anticancer Res. |
pmid:16101188
|
Miller CS et al. |
Salivary biomarkers of existing periodontal disease: a cross-sectional study. |
2006 |
J Am Dent Assoc |
pmid:16570465
|
Mazziotti G et al. |
Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. |
2006 |
Eur. J. Endocrinol. |
pmid:16498049
|
Iwasaki Y et al. |
Uremic toxin and bone metabolism. |
2006 |
J. Bone Miner. Metab. |
pmid:16502128
|
Mandelin J et al. |
Human osteoblasts produce cathepsin K. |
2006 |
Bone |
pmid:16337236
|
Jono S et al. |
Vascular calcification in chronic kidney disease. |
2006 |
J. Bone Miner. Metab. |
pmid:16502129
|
Van Poznak C et al. |
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. |
2006 |
J. Clin. Pathol. |
pmid:16394281
|
Mehrotra M et al. |
Fluid flow induces Rankl expression in primary murine calvarial osteoblasts. |
2006 |
J. Cell. Biochem. |
pmid:16514640
|
Yamamoto T et al. |
Cytokine production in human periodontal ligament cells stimulated with Porphyromonas gingivalis. |
2006 |
J. Periodont. Res. |
pmid:17076781
|
Hsu YH et al. |
Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. |
2006 |
Hum. Genet. |
pmid:16249885
|
Sandra F et al. |
Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. |
2006 |
Oral Oncol. |
pmid:16413220
|
Evans BA et al. |
Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. |
2006 |
J. Bone Miner. Res. |
pmid:16418778
|
Berry JE et al. |
JunB as a downstream mediator of PTHrP actions in cementoblasts. |
2006 |
J. Bone Miner. Res. |
pmid:16418780
|
Yang M et al. |
Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. |
2006 |
Blood |
pmid:16304045
|
Galli C et al. |
Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts. |
2006 |
J. Periodontol. |
pmid:16805686
|
Holding CA et al. |
The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. |
2006 |
Biomaterials |
pmid:16806459
|
Chen G et al. |
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. |
2006 |
Cancer |
pmid:16752412
|
Gannagé-Yared MH et al. |
Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. |
2006 |
Clin. Endocrinol. (Oxf) |
pmid:16712667
|
Rhee EJ et al. |
The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans. |
2006 |
Clin. Endocrinol. (Oxf) |
pmid:16712673
|
Tannehill-Gregg SH et al. |
The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. |
2006 |
Clin. Exp. Metastasis |
pmid:16715352
|
Yang YQ et al. |
Human periodontal ligament cells express osteoblastic phenotypes under intermittent force loading in vitro. |
2006 |
Front. Biosci. |
pmid:16146769
|
Jia L and Jin TY |
Combined effect of fluoride and arsenate on gene expression of osteoclast differentiation factor and osteoprotegerin. |
2006 |
Biomed. Environ. Sci. |
pmid:17190191
|
Yamaguchi M et al. |
RANKL increase in compressed periodontal ligament cells from root resorption. |
2006 |
J. Dent. Res. |
pmid:16861294
|
Grzegorzewska AE and MÅ‚ot M |
Serum markers of bone turnover in dialyzed patients separated according to age. |
2006 |
Int Urol Nephrol |
pmid:16868703
|
Robertson KM et al. |
Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in osteoclast differentiation and activation. |
2006 |
J. Bone Miner. Res. |
pmid:16869726
|